Eisai
Develops pharmaceutical therapies in oncology and neurology for patients with serious diseases
Highlights
- New on EvolcAdded 2026-10-28
About Eisai
Eisai is a pharmaceutical company focused on research and development in oncology and neurology. Its therapeutic areas include epilepsy, Alzheimer's disease and breast cancer.
The company works with patients, healthcare professionals and public authorities, and supports access to therapies and patient care.
EISAI SAS was founded in 1996 and is headquartered in Puteaux, France.
Product: Research and development of pharmaceutical therapies in oncology and neurology.
Public tenders won
1 tender won since 1 Jan 2024 from 1 public buyer in France. From EU award notices (TED) that name Eisai by its registry number.
- 16 May 2025 GCS GRAPS GRAND EST · Fourniture de spécialités pharmaceutiques au profit des adhérents du GCS GRAPS Grand Est notice
Jobs at Eisai
More biotech & pharma companies
Eligo Bioscience
In vivo microbiome gene-editing technologies for developing targeted therapies for human diseaseNew on EvolcEmka Technologies
Telemetry, ECG and physiological monitoring systems and software for preclinical research labs working with rodents and large animalsNew on EvolcRemote-friendlyEmulseo
Microfluidic chemicals and custom development services for research, diagnostics and industrial applicationsNew on EvolcEnnolys
Contract fermentation, purification and drying for biotech and ingredient companies, from scale-up to industrial productionNew on EvolcEnterome
Developing microbiome-derived immunotherapy drugs for patients with cancer and other immune diseasesNew on EvolcEnyo Pharma
Clinical-stage biopharma developing oral vonafexor for chronic kidney disease and Alport syndromeNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Apache
- Google reCAPTCHA
- PHP
- WordPress
- jQuery